Definitive Healthcare (NASDAQ:DH) Trading 6.8% Higher - What's Next?

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report)'s share price rose 6.8% on Tuesday . The stock traded as high as $4.91 and last traded at $4.94. Approximately 899,586 shares changed hands during trading, an increase of 15% from the average daily volume of 781,061 shares. The stock had previously closed at $4.62.

Analyst Ratings Changes

A number of research firms recently commented on DH. Barclays reiterated an "underweight" rating and issued a $4.00 price target on shares of Definitive Healthcare in a research note on Monday, January 13th. Stephens began coverage on Definitive Healthcare in a research note on Friday, December 20th. They issued an "equal weight" rating and a $5.00 price target for the company. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $5.72.

Definitive Healthcare Stock Performance

The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The stock has a 50 day simple moving average of $4.42 and a 200 day simple moving average of $4.44. The company has a market capitalization of $561.43 million, a price-to-earnings ratio of -1.57, a P/E/G ratio of 3.70 and a beta of 1.41.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.03). The business had revenue of $62.70 million for the quarter, compared to the consensus estimate of $61.66 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. During the same period last year, the firm posted $0.01 EPS. As a group, analysts anticipate that Definitive Healthcare Corp. will post 0.15 earnings per share for the current fiscal year.

Insider Activity

In related news, insider William Moschella sold 45,000 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total transaction of $211,500.00. Following the sale, the insider now owns 433,830 shares of the company's stock, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.84% of the company's stock.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Renaissance Technologies LLC increased its holdings in shares of Definitive Healthcare by 50.5% in the second quarter. Renaissance Technologies LLC now owns 28,900 shares of the company's stock valued at $158,000 after buying an additional 9,700 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Definitive Healthcare in the second quarter valued at $127,000. Marshall Wace LLP bought a new position in shares of Definitive Healthcare in the second quarter valued at $1,535,000. AQR Capital Management LLC bought a new position in shares of Definitive Healthcare in the second quarter valued at $155,000. Finally, Millennium Management LLC bought a new position in shares of Definitive Healthcare in the second quarter valued at $9,283,000. Institutional investors own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.